Migraine's $5B Market and the PACAP Names No One Is Pricing

Migraine is one of the most common disabling conditions on the planet, affecting roughly one billion people and ranking as the leading cause of disability in people under 50, and it is quietly a $5 billion-plus drug market that almost no retail biotech investor is watching. The reason is boring: the CGRP antibody and gepant era is mature, the revenue is consolidating around a handful of mega-caps, and the drugs work well enough that there is no obvious disruption story. The action is not in CGRP anymore. It is one mechanism over, in PACAP, where a Phase 2b win from Lundbeck just validated the target and a single pre-data pure play is sitting on the Nasdaq. That is where the binary upside lives, and it is exactly where nobody is looking.

The market is real, and AbbVie owns the anchor. The CGRP class generated roughly $5 billion in 2025 sales. AbbVie’s oral franchise is the clearest proof of where the money is going. Ubrelvy did $392 million in the second quarter of 2026, up 16% year over year, and Qulipta did $350 million, up 30.9%. That is $742 million in a single quarter from two oral gepants, and Qulipta is still growing 30% while the injectable antibodies have long since plateaued. Why orals are winning is simple: a pill beats a monthly self-injection for a disease patients treat at home, often for years. The injectable CGRP antibodies, Amgen’s Aimovig, Lilly’s Emgality, and Teva’s Ajovy, built the category, but the oral gepants, AbbVie’s Ubrelvy and Qulipta and Pfizer’s Nurtec, are the ones taking incremental share. The older acute standard, triptans like sumatriptan, still handles most attacks because it is generic and cheap, but it does nothing to prevent them, which is where the preventive market and its $5 billion of annual revenue come from. AbbVie’s Q2 breakdown, including the Skyrizi, Ubrelvy and Qulipta figures, is here. The migraine franchise also sits inside the broader neurology catalyst picture covered elsewhere. See the neuroscience 2026 catalyst roundup here.

The next wave: PACAP, and Lundbeck just cleared the bar. The PACAP pathway sits next to CGRP in migraine biology but is distinct enough that it could work in the roughly half of patients who do not get adequate relief from CGRP drugs. In June, Lundbeck reported that bocunebart, its intravenous anti-PACAP antibody, met the primary endpoint in the Phase 2b PROCEED trial: a 4.24-day reduction in monthly migraine days versus 2.86 days for placebo, a 1.38-day treatment difference with a p-value of 0.0178. Monthly migraine days is the standard preventive endpoint. The trial enrolled 429 patients who had already failed one to four preventive therapies, the hardest population to treat. Safety looked clean, with treatment-emergent adverse events in 37.7% of bocunebart patients versus 32.7% on placebo and serious adverse events in 0.7% of both arms. Two caveats matter. The subcutaneous arm of the trial hit a futility boundary and was dropped, so the efficacy signal is specific to the intravenous formulation, which is a commercial handicap in a convenience-driven market. Lundbeck already knows this dynamic firsthand: Vyepti, its approved CGRP antibody, is the only intravenous drug in the class, and it has consistently been the laggard versus the subcutaneous antibodies and oral gepants for exactly that reason. And a 1.38-day placebo-adjusted benefit is meaningful but modest, roughly in line with what the oral gepants deliver. Lundbeck is advancing bocunebart to Phase 3 regardless. The PROCEED Phase 2b data and the 1.38-day treatment difference are in Lundbeck’s announcement.

The cautionary base rate is real. PACAP has burned two of the biggest drugmakers in the world. Eli Lilly took its anti-PACAP antibody LY3451838 into Phase 2, failed to show superiority, and scrapped the program in 2022. Amgen’s earlier anti-PACAP antibody also failed in Phase 2. The LY3451838 clinical evaluation is published in Cephalalgia. This is the honest context for every PACAP bull case: the target is real but it has already consumed two big-pharma attempts, and Lundbeck’s own subcutaneous arm failed futility. Anyone buying the PACAP story is betting that the third or fourth formulation finally gets it right, not that PACAP is a guaranteed winner.

Slate Medicines is the only pre-data pure play, and it is pre-proof-of-concept. Slate’s lead asset, SLTE-1009, is a subcutaneous antibody that blocks both PACAP and VIP, and the dual-targeting pitch is that it could beat the PACAP-only drugs on efficacy while offering quarterly dosing. The company reverse-merged onto the Nasdaq through Fulcrum Therapeutics in August with a $245 million private placement that funds it into 2029. Here is the wrinkle for anyone looking at the ticker: the merger does not close until the fourth quarter, so the stock still trades as Fulcrum under the ticker FULC at $3.85, a $294 million market cap, and converts to SLTE at close. SLTE-1009 has not yet produced a single efficacy data point. A Phase 1 healthy-volunteer study is cleared and starting, with data expected in mid-2027, and a Phase 2 dose-ranging study is penciled in for the second half of 2027. Behind it sits SLTE-2100, a bispecific antibody against CGRP and PACAP/VIP that the company plans to move into a Phase 2a proof-of-concept trial in 2027, plus an undisclosed third migraine program. The SLTE-2100 bet is that blocking CGRP and PACAP together could finally get preventive efficacy above the plateau the single-target drugs have hit. It is a smart hedge, but it is also years behind Lundbeck and entirely unproven. This is a pre-proof-of-concept binary, not a de-risked catalyst. The Slate reverse merger and the SLTE-1009 dual PACAP/VIP mechanism are covered here.

The risks are specific, not generic. The subcutaneous problem is the one that could kill the thesis: both Lundbeck’s subcutaneous arm and Lilly’s program failed, and Slate’s entire thesis rests on a subcutaneous formulation working where two predecessors did not. Efficacy bar creep is a separate threat. A 1.38-day placebo-adjusted benefit is what Lundbeck cleared Phase 2 with, and if Phase 3 confirms only that, a PACAP drug with an IV formulation and a modest delta will struggle to displace an entrenched oral gepant on anything but price. The timeline compounds both. Slate’s first efficacy signal is mid-2027 at the earliest, a long time to hold a pre-data name through a binary-averse tape. That is why this is an option, not an investment.

How to trade it. The CGRP incumbents are all mega-caps, and for AbbVie at $462 billion, Ubrelvy and Qulipta together are a rounding error against a franchise anchored by Humira’s successor. The two drugs are running at roughly $3 billion annualized, which is a single-digit slice of a company that books around $15 billion a quarter. Buying AbbVie for its migraine drugs is buying the diversified giant, not the catalyst. The only tradeable pure play on the PACAP next wave is Slate, and it is a pre-data bet with a mid-2027 first look. The honest verdict: own AbbVie if you want the diversified mega-cap, but understand the migraine franchise will not move the stock. If you want the binary, Slate is the only name, and it deserves no more than a 1% to 2% position sized as an option on a mechanism that has already failed twice in big-pharma hands. The PACAP thesis is real, but it is one data point away from being validated or falsified, and that data point is not coming until mid-2027.